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INTRODUCTION
Signal transduction is an event of conversion of
signals from extracellular stimuli to intracellular
responses that lead to change in gene expressions
and cellular phenotypic modulations. Reactive oxygen
species (ROS), generated by a variety of extracellular
and intracellular mechanisms, have gained attention as
novel signal mediators that regulate signal transduction
events. Accumulating evidence suggests that ROS
may be relevant to various cardiovascular diseases
(1-3). In this review, we focused on the generation
of ROS in cardiovascular systems and discussed
ROS-mediated cell signaling, especially the role of
mitogen-activated protein (MAP) kinases, in cardio-
vascular diseases.
ROS has been implicated as a major cause for the
pathogenesis of myocardial ischemia and reperfusion
injury (4, 5). ROS including hydrogen peroxide
(H2O2), superoxide anion radical (O2-), hydroxyl
radical (OH), and peroxynitrite (ONOO-) have been
shown to increase upon reperfusion of the heart
following ischemia (5-7). In ischemia and reperfused
hearts, many alterations such as contractile dysfunc-
tion, arrhythmias, and changes in gene expression
have been observed (8, 9). These alterations in the
myocardium during ischemia-reperfusion were sug-
gested to be, in part, due to oxidative stress. Clinically,
antioxidants are believed to counteract with ROS
and reduce the incidence of coronary artery disease
(10). Intake of vitamin E decreased the incidence
of cardiovascular events in the population of ischemic
heart disease in the Cambridge Heart Antioxidant
Study (CHAOS) (11). In addition, a multivitamins
and probucol (MVP) trial revealed that an antioxidant,
probucol was effective for prevention of restenosis
after percutaneous transluminar coronary angioplasty
(PTCA) procedure (12).
Based on the above studies, it is suggested that
ROS may also be pathogenic for vascular diseases
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such as atherosclerosis and restenosis. In vivo ex-
periments revealed that the generation of O2- in-
creased in aortas from hyperlipidemic rabbits and
coronary arteries from balloon-injured pigs compared
with control vessels (13). It was also reported that
administration of vitamins C and E decreased O2-
production from injured vessels (14). It is now ap-
parent that change in the redox (reduction-oxidation)
state is involved in the pathogenesis of various cardio-
vascular diseases.
SOURCES AND REACTIONS OF ROS
One of the major sources for ROS is mitochondria
in cells. Mitochondrial respiration converts carbo-
hydrates into high-energymetabolites such as adenosine
triphosphate (ATP). This requires the sequential
oxidation and reduction of the substrates using respi-
ratory complexes. After oxidation by mitochondrial
and plasma membrane oxidases, oxygen is reduced
and the superoxide radical O2- is formed (Fig. 1).
Endoplasmic (sarcoplasmic) reticulum and nuclear
membranes have also been shown to produce O2-
by a reaction of oxidative phosphorylation. The cell’s
endogenous defense system is dismutation of O2-
by superoxide dismutase (SOD) to produce hydrogen
peroxide, H2O2. In biological systems, H2O2 is less
reactive than O2- and is metabolized by catalase or
by peroxidase to form O2 and H2O (Fig. 1). Other
important sources of ROS within cells are the
metabolic by-products from biogenic cascade of
arachidonic acid by cyclooxygenase, lipoxygenase,
and cytochrome p-450 monooxygenase. Xanthine
oxidase and NADH/NADPH oxidase are also O2-
generating enzymes in cells. Xanthine oxidase is
converted from xanthine dehydrogenase and me-
diates nucleotides metabolism, such as xanthine,
to form O2- and uric acid. NADH/NADPH oxidase
is a multi-subunit enzyme that may be amajor source
of O2- generation in the vasculature. The role of
NADH/NADPH oxidase in vascular diseases will be
discussed below. Two other ROS that would be im-
portant in vascular injury are hydroxyl radical (OH)
and peroxynitrite (ONOO-) (Fig. 1). In the presence
of nitric oxide (NO), O2- reacts more rapidly with
NO than with SOD, to form ONOO-. ONOO- readly
reacts with tyrosine to form nitrotyrosine which may
impair the vascular responses to stimuli. OH is a
very reactive ROS that does not exist in large amounts
under physiological conditions. However, under the
presence of iron which may be released from red
blood cells, OH would be generated via the Fenton
reaction (or Haber-Weiss reaction) from H2O2.
ROS-MEDIATED MAP KINASE SIGNALING
ROSmediate activation of MAP kinases in a variety
of cells leads to changes in gene expressions. MAP
kinases are serine and threonine protein kinases
that are activated by various extracellular stimuli and
are encoded by a multigene family (Fig. 2) (15).
MAP kinases are activated by phosphorylation on
Fig.1. Sources of reactive oxygen species (ROS) generated endogenously by cardiovascular cells and key metabolic pathways for
these species. Multiple enzymes may induce ROS generation in cardiovascular cells, these include NADH/NADPH oxidase, xanthine
oxidase, lipoxygenase, cyclooxygenase, p-450 monooxygenase, and the enzymes of mitochondrial oxidative phosphorylation. (O2 -,
superoxide anion radical ; H2O2, hydrogen peroxide ; OH, hydroxyl radical ; ONOO-, peroxynitrite ; SOD, superoxide dismutase.)
(Modified from Ref. 1 and 3 with permission.)
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Threonine (T) and Tyrosine (Y) residues within a
T-X-Y phosphorylation motif, where “X” can be
Glu (E), Pro (P), or Gly (G). Three major classes
of dual-specificity MAP kinases can be defined, based
on their activation motifs (TEY, TPY, and TGY),
which is termed ERK1/2 and BMK1 (also called
ERK5), c-Jun N-terminal protein kinases (JNK, also
called SAPK), and p38, respectively. Activation of the
three classes of MAP kinases is charactreristic for
particular stimuli. For example, growth factors and
phorbol myristate acetate (PMA) activate ERK1/2
strongly, but JNK and p38 kinases, weakly (16).
Hyperosmolar stress and TNF-α are strong stimuli
for p38 (17). Berk et al. have shown that growth
factors and angiotensin II are powerful activators of
ERK1/2 in vascular smooth muscle cells (VSMC)
(18). They also found that ROS activated ERK1/2
when the ROS was O2- (19). In other systems, ROS
activate JNK strongly (20). The specificity for MAP
kinase activation is elucidated, in part, by members
of the MAP kinase and ERK kinase (MEK) family
that exhibit unique pairing with downstream MAP
kinases. MEK1 and MEK2 activate ERK1/2, MKK3
and MKK6 activate p38, and SEK1 (MKK4) and
MKK7 activate JNK. The specificity of activation of
MAP kinases by individual stimuli is reiterated by
specific substrates for each class (Fig. 2). Common
substrates for the MAP kinases are transcription
factors that, upon phosphorylation, induce changes
in gene expression. ERK1/2 phosphorylates ternary
complex factor (TCF)/Elk-1 on sites essential for
transactivation (21). JNK phosphorylates c-Jun and
increases its transcriptional activating potential (22).
ATF2 is phosphorylated and activated by both JNK
Fig.2. Signal transduction pathways for mitogen-activated protein kinases (MAPKs) by oxidative stress in cardiovascular cells.
Shown in a highly schematic linear pattern are modules of kinases that regulate each other in a kinase cascade. For example,
oxidative stress is proposed to activate the small G protein Ras and thereby stimulate MAPK and ERK kinase (MEK) kinase
(MEKK) and subsequent activation of MEK1, which is a regulator of the MAP kinase, ERK1/2. Additionally, it has been shown that
other MAPKs including BMK1, JNK, and p38 may be regulated by oxidative stress. Among the targets for these MAP kinases are
various transcription factors including Elk-1 (ternary complex factor, TCF), c-Jun, ATF-2, and CHOP. (Modified from Ref. 1 and 3
with permission.)
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and p38 (23, 24). BMK1 activates MEF2C transcrip-
tion factors (25).
ROLE OF MAP KINASES IN ISCHEMIA AND
REPERFUSION INJURY IN THE HEART
There is growing evidence thatmultipleMAPkinases
are activated during ischemia and/or reperfusion
and may contribute to the structural and functional
alterations after myocardial ischemia (2). Myocyte
loss during the acute stage of myocardial infarction
involves both apoptotic and necrotic cell death (26-
28). Therefore, it is reasonable to conceive that the
balance of cell survival and death is critical during the
pathological evolution of postischemic cardiac dys-
function. Recent findings elucidated the possible role
of MAP kinases in the balance of cell survival and
death in ischemic myocardium. As shown in Fig. 3,
Yu et al. revealed that three MAP kinase members
(ERK1/2, JNK and p38) were activated in cardiomyocytes
subjected to ischemia and reperfusion (29). They
also showed that ERK1/2 is part of a survival pathway
whereas JNK and p38 mediate the death pathway in
the myocardium, based on experiments with their
specific inhibitors. Among the substrates of ERK,
p90 ribosomal S6 kinase (p90RSK) may mediate
ERK-induced antiapoptotic signaling pathway. p90RSK
is known to regulate gene expression via phosphorylation
of transcription factors including c-Fos, cAMP-responsive
element-binding protein (CREB) and to regulate pro-
tein synthesis by phosphorylation of polyribosomal
proteins and glycogen synthese kinase-3. Recently,
Bonni et al. (30) and Tan et al. (31) reported that
p90RSK phosphorylated the proapoptotic protein
BAD at serine 112, which specifically suppressed
BAD-mediated apoptosis. These findings may imply
that p90RSK and ERK promote cell survival by both
inhibiting components of the cell death machinery
(e.g. BAD) and increasing transcription of prosurvival
genes (e.g. CREB). BMK1 has also been reported
to be an antiapoptotic molecule from the findings of
MEK5 inhibition, immediately upstream from BMK1
(25, 32). It was reported that BMK1 was activated in
ischemia and reperfusion of the guinea pig heart
(33). MEK5 and BMK1 are highly expressed in
cardiomyocytes (33). MEK5-dependent BMK1 ac-
tivation results in the phosphorylation of MEF2A
and MEF2C, transcription factors that belong to the
myocyte enhancer factor-2 (MEF-2) family (25), which
are important regulators of cardiac gene expression.
It has been suggested that the pathways regulated
by JNK and p38 contribute to apoptosis. The mecha-
nisms by which JNK and p38-induced apoptosis are
commonly cell and stimulus specific. For example,
apoptosis induced by growth factor deprivation prin-
cipally mediated through the activation of p38 rather
than JNK (34). In some cells, JNK-mediated apoptosis
has been shown to be involved in ubiquitination
and degradation of p53, which may be regulated by
JNK-mediated phosphorylation of p53 (35). However,
p53 does not appear to be important for hypoxia-induced
apoptosis in cardiomyocytes from the experiments
using p53 knockout mice (36). Therefore, themecha-
nism of JNK-induced apoptosis remains unclear. The
role of p38 in cardiomyocyte apoptosis is controver-
sial because p38 can also induce cardiac hypertrophy.
One reported way to explain the role of p38 in apoptosis
is through its effect on cyclin D1 expression during
cell cycle. It has been reported that the coexpression
Fig.3. Activation of ERK, JNK, and p38 in cardiomyocytes sub-
jected to ischemia and reperfusion. Myocytes were exposed to
ischemia or ischemia followed by reoxygenation for the indi-
cated time period. Cells were harvested and extracted. Endog-
eneous MAPKs were immunoprecipitated, and the activities of
ERK, JNK, and p38 were measured. Top, densitometric analysis
of MAPKs activation. Bottom, representative autoradiogram.
(Cited from Ref. 29 with permission.)
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of MKK3 along with p38 inhibits mitogen-induced
cyclin D1 expression (37). However, contrasting
findings have been reported that p38 phosphorylates
MAPK-activated protein kinase 2 (MAPKAPK2),
which in turn phosphorylates heat shock protein 27
(HSP27) and protects against apoptosis during ischemia
(38). Activation of this pathway is cytoprotective and
overexpression of HSP27 confers protection against
ischemia in cardiomyocytes (39, 40). It was also
reported that activation of p38 and JNK by anisomycin
is cardioprotective (41). The controversies among
studies may be explained by the existence of differ-
ent p38 isoforms such as p38αwhich is proapoptotic
whereas p38β may be antiapoptotic in neonate rat
cardiomyocytes (42). The current evidence for JNK
and p38 suggest multiple roles in ischemia and
reperfusion, preconditioning, and hypertrophy of the
heart. Further studies are needed to define the pre-
cise role of these MAP kinases in ischemia and
reperfusion injury in the heart.
MAP KINASE-MEDIATED VASCULAR RE-
MODELING REGULATED BY ROS
Vascular remodeling is a well described response
of blood vessels to both physiologic and pathologic
stimuli. It was originally defined by the findings that
atherosclerotic vessels undergo a compensatory en-
largement during atherosclerosis by the analysis of
pathologic specimens (43). Recently, vascular re-
modeling was recognized to occur in animal models
of ballon injury (13) and in patients after the PTCA
procedure (44), and has been suggested to relate
to restenosis. Several lines of evidence indicated that
ROS and MAP kinases are involved in vascular re-
modeling under various pathological conditions. For
example, we previously showed that exposure of
vascular smoothmuscle cells (VSMC) toH2O2 altered
MAP kinase activity (Fig. 4) (45). In VSMC, ROS
alters MAP kinase activity (19), protooncogene ex-
pression, and cell growth (46). Recently, it became
clear that intracellular ROS generated by growth fa-
ctors and cytokines may act as second messengers.
Platelet-derived growth factor (PDGF) has been re-
ported to increase intracellular ROS in VSMC (47).
Increasing the intracellular levels of the scavenging
enzyme catalase or the antioxidant glutathione pre-
vented the PDGF-mediated increase in ROS. These
ROS scavengers also blocked PDGF-induced tyrosine
phosphorylation, ERK1/2 activation, DNA synthesis,
Fig.4. ERK, JNK, and p38 activation by hydrogen peroxide (H2O2) in vascular smooth muscle cells (VSMC). Time course (A, B)
with 1 mM H2O2 and the concentration-response curve (C, D) (20 min for ERK1/2, 40 min for JNK, and 60 min for p38) are shown.
Panels A and C are representative autoradiograms. Panels B and D are densitometric analysis of MAPKs activation. (Modified from
Ref. 45.)
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and chemotaxis, suggesting the role of ROS as second
messengers. Activation of ERK1/2 has also been
implicated in vascular endothelial growth factor
(VEGF)-induced vascular endothelial cell (EC) survival
(48). More recently, a general role for ROS in cell
growth was suggested by the findings that v-Ras
transformation was associated with increased ROS
and that augmenting antioxidant defenses with catalase
and SOD inhibited transformation and growth (49).
JNK and p38 are also sensitive to redox modulation
(Fig. 4) (45). Members of the Rho family of small
GTPases including Rac1 regulate these kinases (50).
In contrast to ERK1/2, JNK and their downstream
target c-Jun have been implicated in H2O2 and other
stress-induced apoptosis of ECs (51). Moreover, p38
has been implicated in EC upregulation of intracellular
adhesion molecule-1, and therefore, endothelial dys-
function (52). In VSMC, ROS mediated activation
of p38 has also been implicated in cell migration (53).
Angiotensin II and endothelin are other activators
of MAP kinases in VSMC and are believed to cause
vascular remodeling (54, 55). Very recently, Griendling
et al . showed that angiotensin II rapidly increased
production of ROS via NADH/NADPH oxidase that
reside in cell membranes (Fig. 5) (56). In blood
vessels, a plasmamembrane NADH/NADPH oxidase
accounts for more than 90% of O2- formation (57).
Interestingly, angiotensin II potently activates ERK1/2
and p38 ; however, only p38 is sensitive to both inhi-
bition of NADH/NADPH oxidase activity and catalase
overexpression in VSMC (58, 59). We obtained similar
findings that antioxidants preferentially inhibits JNK
and p38 activation by angiotensin II but not ERK1/2
activation (unpublished observation). p22phox is a
critical component of NADH/NADPH oxidase activity
and transfection of antisense p22phox cDNA to VSMC
inhibited angiotensin II-induced VSMC hypertrophy
via a p38-dependent manner (60). It has also been
reported that thrombin, TNF-α, and lactosylceramide
also stimulate NADH/NADPH oxidase-dependent
O2- generation in VSMC (61-63). In ECs, mechanical
forces stimulate NADH/NADPH oxidase (64), but
agonist responsiveness remains to be elucidated. Of
note, NADH/NADPH oxidase is regulated at the pro-
tein level and may be increased by hormonal stimuli.
For example, TNF-α increasesNADH/NADPHoxidase
activity in VSMC over 24 hours, an event that is
dependent on increased transcription of p22phox
(62). p22phox mRNA and O2- production are upregulated
in the aortas of rats made hypertensive by angiotensin
II infusion (65). It has become obvious that various
vasoactive substances activate NADH/NADPHoxidase
and produce ROS as second messengers in vascular
cells. However, involvement of other sources of
ROS, such as xanthine oxidase, lipoxygenese, and
cyclooxygenase cannot be ruled out. It was recently re-
ported that lipoxygenase metabolites of arachidonic acid
mediate angiotensin II stimulation of theNADH/NADPH
oxidase in VSMC (66). Further information concerning
the activation mechanisms of the oxidase and protein
targets of the oxidase-derived ROS should be clarified.
Fig.5. Structure and components of NADH/NADPH oxidase. Left side panel shows the scheme of the resting state of the compo-
nents. Mitogenic oxidase-1 (mox-1) and p22phox form the electron transfer components of the oxidase, and p47phox and p67phox
are cytosolic components that interact with these 2 proteins to modulate its activity. The small G protein Rac also serves a regulatory
function. Right side panel shows the activated state of NADH/NADPH oxidase induced by agonists such as angiotensin II, endothelin,
and PDGF etc.
M. Yoshizumi et al. ROS and MAP kinase in cardiovascular disease１６
OTHER SIGNALING MOLECULES ACTI-
VATED BY ROS
Although MAP kinases play a central role in
ROS-mediated signal transduction in cardiovascular
diseases, other signaling molecules also involved in
ROS-mediated phenomena in cells. ROSparticipate in signal
transduction by generating classic second-messengers
(calcium and lipid mediators) that transmit the signal
to intracellular mediators in both the cytoplasm and
nucleus (Fig. 6).
Calcium-dependent signal transduction by ROS
ROS stimulate increases in calcium via at least
three pathways. First, intracellular calcium release
from endoplasmic (sarcoplasmic) reticulum occurs
by generation of IP3, which binds to an IP3-sensitive
calcium channel in endoplasmic (sarcoplasmic) re-
ticulum. In addition, ROS may directly increase the
open probability of calcium release channels. Pre-
viously, we reported that angiotensin II and endothelin,
potent activators of NADH/NADPH oxidase as men-
tioned above, increased intracellular calcium in
cardiomyocytes (67) and VSMC (68, 69). Moreover,
a calcium-ATPase is required to maintain calcium
within the IP3-sensitive pool, and inhibiting this ATPase
would increase intracellular calcium (70). Secondly,
in several cell types, ROS have been shown to stimu-
late extracellular calcium entry by effects on channels
(71) and the sodium-calcium exchanger (72). Thirdly,
mitochondria also store intracellular calcium, and
significant oxidative stress inhibits this ability resulting
in a release of calcium, especially in response to
oxidized pyridine nucleotides (73, 74).
Phospholipid-dependent signal transduction by ROS
The finding that ROS increased intracellular calcium
indicated that phospholipases were activated by
ROS, because generation of IP3 from PIP2 is a well
established mechanism in cardiovascular cells for the
release of calcium from intracellular stores (75). At
least three important phospholipases have been shown
to be activated by ROS : phospholipase A2 (PLA2),
phospholipase C (PLC), and phospholipase D (PLD).
PLA2 is likely activated by increases in intracellular
calcium. It is important to note that many lipids gen-
erated by PLA2 may themselves generate ROS through the
action of monooxygenases. PLC is a calcium-dependent
phospholipase that hydrolyses PIP2 to generate IP3
and diacylglycerol. Although there are no published
Fig.6. Redox regulation of signal transduction components. In addition to generation of intracellular O2 - by the enzymes, dis-
cussed in Fig. 1, extracellular stimuli including lipophilic substrates, membrane permeable oxidants (H2O2), cytokines and growth
factors may modulate cellular redox state. The increased levels of reactive oxygen species (ROS) may act as second messengers to
activate MAPKs, tyrosine kinases, and NF-κB, as well as inhibit protein tyrosine phosphatase (PTPase). As a consequence, there are
alterations in the phosphorylation and activity of transcription factors, resulting in promotion of gene expression. (RTK, receptor
tyrosine kinase ; PKC, protein kinase C) (Modified from Ref. 1 and 3 with permission.)
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findings to suggest that ROS directly activate PLC,
generation of ROS may be an early event in growth
factor dependent signaling and activation of PLC.
PLD has been shown to be stimulated by H2O2, fatty
acid hydroperoxides (75, 76), and 4-hydroxynonenal
in endothelial cells. Further studies are required
to elucidate the mechanisms by which phospholipases
are activated.
Tyrosine kinases as mediators of ROS-sensitive
pathways
Tyrosine kinases are important as intracellular
mediators because they are among the kinases most
rapidly activated by many stimuli including ROS.
Many growth factor receptors contain tyrosine kinase
domains in their cytoplasmic portions (Fig. 6). Thus,
a proximate signal event in growth factor signal
transduction is receptor dimerization and activation
of intrinsic tyrosine kinase. To date, there is no direct
evidence that ROS stimulate receptor tyrosine kinases ;
however, three mechanisms have been proposed
by which ROS activate tyrosine kinases. Firstly, tyrosine
kinases may be activated by ROS directly by altering
protein-protein interactions depending on sulfhydryl
groups. Secondly, inhibition of phosphotyrosine
phosphatases (PTPases) may be another important
mechanism by which ROS activate tyrosine kinases.
All PTPases contain a redox-sensitive cysteine at
their active site (77), and oxidation of the sulfhydryl
group inactivates the PTPase. Since many tyrosine
kinases are inactivated by PTPases, oxidation of
PTPases would stimulate tyrosine kinases. Thirdly,
oxidation has been shown to stimulate proteolysis of
regulatory proteins that may inhibit tyrosine kinase
activation. Several tyrosine kinases are activated by
ROS, among which Src family kinases have been
described most frequently. p60Src, p56Lck, and p59Fyn
of the Src family members have been found to be acti-
vated by H2O2 and other ROS. Two other ROS-sensitive
tyrosine kinases identified in white blood cells are
Syk and ZAP-70 (78). Of note, specific Src family kinases
stimulate specific pathways leading to selective ac-
tivation of MAP kinases. We previously found that
c-Src mediates H2O2-induced JNK activation in VSMC
(45). Abe et al. reported that BMK1 is activated via
c-Src (58) whereas ERK1/2 is activated by Fyn (79).
These findings indicate that c-Src and Fyn have sepa-
rate role in ROS-mediated signal transduction. In ad-
dition, another tyrosine kinase Pyk2, a FAK related
kinase, has been shown to be activated by ROS (80)
and may activate other MAP kinases.
Small G proteins in ROS-sensitive signal transduction
Other important mediators of the ROS-sensitive
signaling pathway are small G proteins. From the
experiments with recombinant p21Ras in vitro, it was
found that ROS directly promoted guanine nucleotide
exchange on p21Ras (81). Furthermore, H2O2 acti-
vation of ERK2 was abolished by expression of domi-
nant negative RasN-17 (49) or by treating with a
farnesyltransferase inhibitor. Another small G protein,
Rac may also regulate ROS production (Figs. 2, 6)
(82). Expression of constitutively active V12-Rac1
in HeLa cells or stimulation with cytokine resulted
in a significant increase in intracellular ROS. Treat-
ment of cells with antioxidants inhibited the increase
in ROS that occurred following V12-Rac1 expression.
Potential mechanisms for small G protein activation
include alterations of the lipid environment and in-
hibition of post-transcriptional modifications, such as
palmitoylation, which may regulate small G protein
activity.
ROS-induced activation of transcription factors:
NF-κ B and AP-1
Transcription factors are proteins that move to
the nucleus upon activation and trigger gene expres-
sions (Fig. 6). Nuclear factor-κB (NF-κB) is an inducible
transcription activator that is a likely target for ROS
signal transduction. NF-κB is a heterodimer contain-
ing a 50- and a 65-kD subunit (termed p50 and p65).
There are two forms of NF-κB in the cell, an inactive
form in the cytosol and an active form in the nucleus.
Cytosolic NF-κB activation can be brought about by
a variety of stimuli including cytokines, physical stress
such as UV and ionizing radiation, and oxidants such
as H2O2 (82-84). Activation of NF-κB by ROS may
be pathogenic for atherosclerosis, as NF-κB can be
activated in response to low-density lipoproteins
(LDLs), an atherogenic diet, and advanced glycation
end products (AGEs). In addition, recognition sequences
for NF-κB are present in genes whose expression
causes monocyte adhesion to endothelial cells and
activation, such as E-selectin, vascular cell adhesion
molecule-1 (VCAM-1), and intracellular adhesion
molecule-1 (ICAM-1).
In addition to NF-κB, activator protein-1 (AP-1)
appears to be activated by ROS (85). Regulation of
AP-1 by ROS has been shown to involve ERK1/2
(86) and JNK (87) in a cell-and stimulus-specific man-
ner. For example, metabolic oxidative stress in the
liver increased AP-1 activity and stimulated binding
of c-Fos, c-Jun, ATF-2, JunB, and JunD (87). ERK1/2
was shown to be necessary for phosphorylation of
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the transcription factor Elk-1 and induction of the
c-fos serum response element (86). In vascular smooth
muscle, expression of mRNAs for c-fos and c-jun are
rapidly induced by H2O2 and by arachidonic acid
metabolites including 15-HETE and linoleic acid
metabolites such as hydroperoxyoctadecadienoic
acids (HPODEs) (88-90). Since these same stimuli
also activate ERK1/2 in smooth muscle (19), it is
likely that ERK1/2 play an important role in AP-1
activation. We also observed that endothelin-1 stimu-
lates AP-1 activation probably through the activation
of ERK1/2 in VSMC (55). Other transcription fac-
tors such as hypoxia-inducible factor-1 (HIF-1) and
early growth response-1 (Egr-1) may be involved
in ROS-mediated events and were described else-
where (91, 92).
CLINICAL IMPLICATIONS OF ROS AND MAP
KINASES IN CARDIOVASCULAR DISEASE
Although the role of MAP kinases in cardiac hyper-
trophy and apoptosis has been described in in vivo
and in animal models, the role in human disease is not
well documented. Recently, it was demonstrated that
the expression of threeMAP kinase members, ERK1/2,
JNK, and p38 were confirmed in human heart (93).
A potential clinical relevance for their action was re-
ported by an increased activity of JNK and p38 in
heart failure secondary to ischemic heart disease
which may relate to ROS generation. It was also re-
ported that activation of ERK1/2, JNK, and p38 was
observed in human heart during coronary artery by-
pass grafting surgery (94). However, the clinical sig-
nificance of MAP kinase activation in ischemia and
heart failure of humans still remains to be elucidated.
Gene transfer techniques provide insight into the
role of MAP kinases in cardiac disease. In the gene
transferred rat of dominant-negative SEK1, immediately
upstream from JNK, cardiac hypertrophy was inhi-
bited as evaluated by echocardiography and biochemical
markers (95). In addition, an upstream regulator of
p38, TAK1 was activated in cardiac hypertrophy of
transgenic mice and TAK1 activation resulted in heart
failure (96). These findings suggest the role of MAP
kinases in cardiac disease, and therefore,MAPkinases
are potential drug targets in the treatment of the
disease.
Three vascular process in which ROS are likely to
play a pathogenic role are hypertension, atheroscle-
rosis, and vascular remodeling. Recently, it was shown
that angiotensin II-induced hypertension was asso-
ciated with increased vascular O2- production and that
treatment with SOD reduced blood pressure by 50
mmHg in angiotensin II-infused rat (97). In addition,
it was reported that the increase in MAP kinase ac-
tivity was sustained in the angiotensin II-infused rat
(98). These findings suggest that hypertension caused
by chronically elevated angiotensin II andMAP kinase
activity is mediated in part by O2-. Increases in ROS
may affect the pathogenesis of atherosclerosis.
Hypercholesterolemic animals and patients exhibit
impaired endothelial dependent relaxation that can
be restored with antioxidants (99). Clinically, it was
also observed that vascular superoxide production by
NADH/NADPH oxidase is associated with endothelial
dysfunction in patients with hypercholesterolemia
(100). ROS also cause oxidative modification of LDL,
promoting uptake by the scavenger receptor and foam
cell formation (101). These findings strongly suggest
that the vascular redox state plays a pathogenic role
in atherosclerosis. Vascular remodeling is also a
ROS-sensitive phenomenon occuring clinically. It was
reported that p22phox, a component of NADH/NADPH
oxidase, expressed highly in the atherosclerotic re-
modeled specimens of the coronary artery (102).
NADH/NADPH oxidase is a potent mediator of MAP
kinase activation as mentioned above. Recent findings
revealed that remodeling occurs in patients after the
PTCA procedure (44) and remodeling is a key process
for restenosis (103). The findings that antioxidants
inhibit restenosis both in vivo (13) and clinically (12)
may imply the role of ROS in vascular remodeling.
FUTURE DIRECTIONS
As discussed above, significant progress has been
made in identifying and characterizing the sources
of ROS and the role of MAP kinases in cardiovascular
diseases. However, significant work should be per-
formed to resolve the remaining issues. Firstly, ad-
ditional information is required to clarify what mol-
ecule is really responsible for ROS generation in
different cardiovascular cells including EC, VSMC,
and cardiomyocytes. In addition, identification of the
enzymatic and protein targets of ROS should be im-
portant. Of course, the ultimate goal is the develop-
ment of new therapeutic strategies for the treatment
of cardiovascular diseases of which ROSmay be in-
volved, in part, or in total. Understanding the molecular
mechanisms of ROS generation and ROS-mediated
alterations of signaling molecules including MAP
kinases may provide insights into the pathogenesis
of various cardiovascular diseases. Searching for ROS
generating and ROS-mediated signaling molecules
１９The Journal of Medical Investigation Vol. 48 2001
is now ongoing in our labs and will inform help iden-
tify targets for the emerging therapeutic paradigm
of gene therapy.
During the revision of this review, it has been re-
ported that Gαi and Gαo, subunits of heterotrimeric
G protein, are potential targets of oxidative stress
for activation of ERK (104).
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